Drug Trial Radar · NCT04204616
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jan 11, 2021
Primary completion
Oct 26, 2026
Study completion Oct 26, 2026
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Conditions
- Prurigo Nodularis
Interventions
NemolizumabDrug
Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) by SeverityTime frame: Up to 192 weeks
Locations
164 sites in 16 countries. Site status is shown where the registry gives one.
Galderma Investigational Site
Birmingham, Alabama
Galderma Investigational Site
Birmingham, Alabama
Galderma Investigational Site
Fountain Valley, California
Galderma Investigational Site
Los Angeles, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
San Diego, California
Galderma Investigational Site
Santa Monica, California
Galderma Investigational Site
Washington D.C., District of Columbia
Galderma Investigational Site
Aventura, Florida
Galderma Investigational Site
Delray Beach, Florida
Galderma Investigational Site
Hollywood, Florida
Galderma Investigational Site
Largo, Florida
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
Miami, Florida
Galderma Investigational Site
North Miami Beach, Florida
Galderma Investigational Site
Ormond Beach, Florida
Galderma Investigational Site
Pembroke Pines, Florida
Galderma Investigational Site
Tampa, Florida
Galderma Investigational Galderma Investigational Site
Columbus, Georgia
Galderma Investigational Site
Macon, Georgia
Galderma Investigational Site
Newnan, Georgia
Galderma Investigational Site
Chicago, Illinois
Galderma Investigational Galderma Investigational Site
Chicago, Illinois
Galderma I Galderma Investigational Site
Lake Bluff, Illinois
Galderma Investigational Site
Indianapolis, Indiana
Galderma Investigational Site
Topeka, Kansas
Galderma Investigational Site
Louisville, Kentucky
Galderma Investigational Site
Baltimore, Maryland
Galderma Investigational Site
Boston, Massachusetts
Galderma Investigational Site
Ann Arbor, Michigan
Galderma Investigational Site
Saint Joseph, Michigan
Galderma Investigational Site
Saint Joseph, Missouri
Galderma Investigational Site
St Louis, Missouri
Galderma Investigational Site
Henderson, Nevada
Galderma Investigational Site
New York, New York
Galderma Investigational Galderma Investigational Site
New York, New York
Galderma Investigational Site
High Point, North Carolina
Galderma Investigational Site
Raleigh, North Carolina
Galderma Investigational Site
Winston-Salem, North Carolina
Galderma Investigational Site
Cincinnati, Ohio
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.